Effects of Rivastigmine on Brain Functional Networks in Patients With Alzheimer Disease Based on the Graph Theory. Issue 1 (January 2021)

• Record Type: Journal Article
• Authors: Zhang, Jiangtao; Cheng, Jianan; Yang, Hua
• Is Part Of: Clinical neuropharmacology. Volume 44:Issue 1(2021)
• Publication Date: 2021-01
• Subjects: Alzheimer disease -- rivastigmine -- rs-fMRI -- brain network -- graph theory; Neuropharmacology -- Periodicals; 615.78
• DOI: 10.1097/WNF.0000000000000427
• Languages: English
• ISSNs: 0362-5664

Abstract

Abstract : Objective: The aim of this study was to explore the effect of rivastigmine on brain function in Alzheimer disease (AD) by analyzing brain functional network based on the graph theory. Methods: We enrolled 9 patients with mild to moderate AD who received rivastigmine treatment and 9 healthy controls (HC). Subsequently, we used resting-state functional magnetic resonance imaging data to establish the whole-brain functional network using a graph theory–based analysis. Furthermore, we compared systemic and local network indicators between pre- and posttreatment. Results: Patients with AD exhibited a posttreatment increase in the Mini-Mental State Examination scores and a decrease in the Alzheimer's Disease Assessment Scale cognitive subscale scores and activities of daily living. The systemic network for HC and patients with AD had good pre- and posttreatment clustering coefficients. There was no change in the C p, L p, Gamma, Lambda, and Sigma in patients with AD. There were no significant between-group differences in the pre- and posttreatment systemic network measures. Regarding the regional network, patients with AD showed increased betweenness centrality in the bilateral caudate nucleus and right superior temporal pole after treatment with rivastigmine. However, there was no between-group difference in the pre- and posttreatment betweenness centrality of these regions. There were no significant correlations between regional network measure changes and clinical score alterations in patients with AD. Conclusions: There are similar systemic network properties between patients with AD and HC. Rivastigmine cannot alter systemic network attributes in patients with AD. However, it improves the topological properties of regional networks and between-node information transmission in patients with AD.